Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 8:44:102158.
doi: 10.1016/j.eucr.2022.102158. eCollection 2022 Sep.

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report

Midori Hara  1 , Satoru Kira  1 , Manabu Kamiyama  2 , Tatsuya Ihara  1 , Takeshi Sato  3 , Takahiko Mitsui  1
Affiliations
Case Reports

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report

Midori Hara et al. Urol Case Rep. .

Abstract

Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments.

Keywords: Neuroendocrine prostate cancer; Peptide receptor radionuclide therapy; Tumor mutational burden high.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Somatostatin recepter scintigraphy scan Somatostatin receptor scintigraphy reveals multiple metastasis of lymph nodes, bones, and lungs of neuroendocrine prostate cancer.
Fig. 2
Fig. 2
Timecourse for PSA, interventions, and status of disease on Fluorodeoxyglucose-positron emission tomography (FDG-PET/CT) (A) Timecourse for PSA and interventions (B) Timecourse for tumor markers including CEA, NSE, and ProGRP, and interventions, and status of these tumors before and after cisplatin and etoposide therapy after six cycles.
Fig. 3
Fig. 3
Immunohistochemical staining of neuroendocrine prostate cancer (A) Immunohistochemical staining reveals positive expression of chromogranin A. (B) Immunohistochemical staining reveals positive expression of synaptophysin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nadal R., Schweizer M., Kryvenko O.N., et al. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11:213. - PMC - PubMed
    1. Shevrin D.H. Genomic predictors for treatment of late stage prostate cancer. Asian J Androl. 2016;18:586. - PMC - PubMed
    1. Okasho K., Ogawa O., Akamatsu S. Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Transl Androl Urol. 2021;10:3953. - PMC - PubMed
    1. Strosberg J., El-Haddad G., Wolin E., et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125. - PMC - PubMed
    1. Galuppini F., Dal Pozzo C.A., Deckert J., et al. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int. 2019;19:209. - PMC - PubMed

Publication types

LinkOut - more resources